

18, 19 & 20 April 2011
Papendal Hotel and Conference Centre, Arnhem

2nd Announcement



Opening ceremony with
His Royal Highness the Prince of Orange

Keynote speakers include:

Joan W. Bennett
Harald zur Hausen
Lynn Margulis
Barry Marshall
Paul Nurse
J. Craig Venter

www.nvmm.nl

www.100-years-nvmm.nl

This is the time to choose efficacy first

**Invasive Aspergillosis:
use VFEND® first-line**

Higher Efficacy

VFEND® demonstrated better responses and improved survival when compared to Amphotericin B in Invasive Aspergillosis¹

Broad Spectrum

VFEND® is indicated for the first-line treatment of:

- Invasive aspergillosis
- Candidemia in non-neutropenic patients
- Serious fungal infections caused by *Scedosporium* spp. and *Fusarium* spp.

Flexibility

VFEND is available in IV and oral formulation



EFFICACY WHEN IT MATTERS MOST

Introduction

The spring meeting of the two Dutch Microbiological Societies (NVMM & NVvM) will be held on April 18, 19 and 20, 2011 in Papendal. This year is a very special year, we are celebrating the 100th anniversary of the Dutch Society of Microbiology, the NVvM. NVvM, we congratulate you with this. For this reason the program will cover three whole days and several very renowned international speakers will highlight major achievements in Microbiology through the years. On day 1, **Lynn Margulis, Joan W. Bennett, J. Craig Venter**, and the Nobel laureates **Harald zur Hausen, Barry Marshall and Paul Nurse** will present their impressive work. His Royal Highness the Prince of Orange will be present during the opening ceremony.

At day 2 and 3 the program will consist of various sessions with a wide variety of timely microbiological themes presented by prominent national and international speakers. As always, also our young microbiologists from research centers throughout the Netherlands will present their most novel and promising data on these days.

Throughout the program you will find special events aimed at the 100th NVvM-anniversary. There will be microbiology and art events, a special centenary book, a special centenary micro-beer and much more. The poster sessions will be on Monday en Tuesday evening, of course with free drinks. On Tuesday evening there is the usual dinner and party, this year even more splendid and thrilling as before. Be sure to stay awake until midnight!! This is the start of April 20th and at that moment it is EXACTLY 100 years ago that the NVvM was founded.

As always, several prizes will be awarded, both from NVMM and NVvM. The award ceremony will be an integral part of the Monday program. On Tuesday afternoon, the SKMM prize will be awarded and the director of ARTIS will present the plans for the realization of the MicroZoo.

To award young scientists for their contribution, the Stichting Antonie van Leeuwenhoek will waive both the admission fee as well as the hotel costs of presenting PhD students (poster or talk).

We hope to see you all in Papendal and look forward to an inspiring meeting and share new data and insight in Microbiology in all its aspects. And, especially this year, it will be great fun.

The organizing committee

Microbiology awards 2011

- | | |
|-------------------------------|---|
| Poster prizes | Three poster prizes will be awarded for the best poster presentations (1st prize: Euro 200, 2nd & 3rd prize: Euro 100) |
| Kiem prize (Kiemprijs) | Three Kiem prizes, Euro 500 each, will be awarded to three PhD-students for a first scientific paper. |
| Best thesis award | The best thesis within the broad area of microbiology will be awarded with an amount of Euro 1000. |
| Postdoc award | A prize of Euro 2000 is awarded to the postdoctoral fellow with the best achievements in microbiology in the preceding years. |

All prizes cover the areas of Microbiology in the broadest sense: Parasitology, virology, bacteriology, mycology, molecular studies, epidemiological studies, clinical microbiology, microbe-host interaction, biotechnological aspects and further. Four committees will judge the proposals.

Award announcements

During the scientific programme on Monday the winners of the Kiem prize, Best thesis award and Postdoc award will be announced.

The poster prize will be announced on Tuesday evening after the poster session.

Organizing committee

Prof. dr. J.A.G. van Strijp, chair
Dr. A.J.W. van Alphen
Dr. W. Bitter
Prof. dr. S. Brul
Prof. dr. L. Dijkhuizen
Dr. B. Duim
Prof. dr. J.M.D. Galama
Dr. J.W.B. van der Giessen
Prof. dr. ir. M.S.M. Jetten
Prof. dr. M.P.G. Koopmans
Prof. dr. P. Rottier
Prof. dr. P.H.M. Savelkoul
Prof. dr. L.J. Stal
Dr. B.J.M. Vlamincx
Dr. M.J.H.M. Wolfhagen
Prof. dr. H.A.B. Wösten
Prof. dr. ir. M.H. Zwietering

Poster committee

Drs. L.M. Kortbeek, chair
Dr. W. van Schaik
Dr. A.M. Wensing
Prof. dr. ir. M.H. Zwietering

The Scientific spring meeting is organized by the Dutch Society of Medical Microbiology (NVvM) and the Dutch Society of Microbiology (NVvM).

Congress secretariat:



P.O. Box 2428
5202 CK 's-Hertogenbosch
Tel 073 - 700 35 00
Fax 073 - 700 35 05
info@congresscompany.com
www.congresscompany.com

*Cover photo: Antonie van Leeuwenhoek; leadlight window (1959-60) by Johan Dijkstra (1896-1978).
The leadlight window is owned by the University Medical Center Groningen. The photo has been made
by Gjalt Welling.
Other photo's: NVvM*

General information

Dates

Monday 18, Tuesday 19 & Wednesday 20 April 2011

Venue

Papendal Hotel en Conference Centre
Papendallaan 3
Arnhem
Tel 026 - 483 79 11

Website

Please check www.nvmm.nl or www.100-years-nvmm.nl for registration and up-to-date programme information and for more information on the NVMM or NVvM.

Language

The language will be English during the scientific sessions.

Identification

His Royal Highness The Prince of Orange will visit the congress on Monday morning. Because of safety regulations please make sure you bring your passport/identification card. It is possible that you will be asked to identify yourself.

Accreditation

The Scientific Spring Meeting 2011 is accredited by the NVMM with 6 points per day (18 points in total). Please note that in order to receive accreditation you need to supply the congress secretariat with your BIG-number.

Certificate of attendance

Certificates of attendance should be collected at the registration desk in the afternoon of the last day of your attendance.

Registration

Please register yourself on line via www.nvmm.nl or www.100-years-nvmm.nl.

Registration fee (incl. NTMM supplement, coffee, tea and lunch)

	per day (Tuesday or Wednesday only)	3 days
Members NVMM/NVvM	Euro 110	Euro 200
Non-members	Euro 160	Euro 300


Young Investigator's Grant

The registration fee for presenting PhD-students and AIOS' (oral or poster, presenting author only) will be waived.

Grant "Antonie van Leeuwenhoek Stichting"

The "Antonie van Leeuwenhoek Stichting" supports PhD-students and AIOS' to attend the spring meeting and therefore they will sponsor the hotel costs (2 nights, 2 persons per room) for presenting PhD-students or AIOS' (poster or oral, presenting author only). Please indicate, when registering, whether you would need a hotel room and provide the name of your roommate.

Please note: Pre-registration is mandatory.



Dinner & party

Dinner Monday 18 April 2011 Euro 50 per person
Dinner & party Tuesday 19 April 2011 Euro 50 per person

Please note: only a limited number of dinner tickets are still available for the dinner on Monday 18 April. Reservations will be accepted on first-come-first-serve basis.

Cancellation

Cancellations and refund requests must be submitted via e-mail to the congress secretariat before 15 February 2011. Cancellations made before 15 February 2011 will be refunded less Euro 30 to administration costs. All refunds will be made after the congress.

Hotel accommodation

At this moment only a limited number of rooms are available in Bilderberg Hotel Wolfheze & Bilderberg Hotel De Buunderkamp. Please check availability and costs when registering on line. Reservations will be accepted on first-come-first-serve basis.

Prices hotel accommodation (including breakfast and tax):

	Single room	Double room
Bilderberg (Wolfheze or De Buunderkamp)	Euro 115	Euro 155

Note: the person who makes the reservation for a double room has to pay the full amount.

Hotel Bilderberg Shuttle Service

A shuttle service between Hotel Bilderberg Wolfheze/De Buunderkamp and Papendal will be provided. Please find below the time schedule. Please note: the departure times are fixed. No continuous service is provided

Time schedule Papendal – Hotel Bilderberg Wolfheze/De Buunderkamp:

Monday 18 April	19:00 / 21:30 / 23:00 hrs
Tuesday 19 April	22:30 / 00:30 / 01:00 hrs
Wednesday 20 April	n/a

Hotel Bilderberg Wolfheze/De Buunderkamp – Papendal (one way):

Monday 18 April	n/a
Tuesday 19 April	08:15
Wednesday 20 April	08:30

Payment

Payment is only possible by a “éénmalige machtiging” for participants with a Dutch bank- or bankgiro account. Other participants will receive payment instructions in their confirmation. On site you can pay cash, via credit card (visa or MasterCard) or by PIN.

Name badges

Name badges will be send, via regular mail, to all participants 2-3 weeks before the start of the congress. All participants should wear their name badge throughout the congress.

Registration desk

The registration desk will be open on Monday, Tuesday and Wednesday from 8:30 – 17:00 hrs.

Instructions for presenters

PowerPoint:

All meeting rooms are equipped with computers and data projectors. Please bring your presentation on a USB-stick to the speaker service center by latest in the break before your presentation. For special audiovisual requirements, please contact the congress secretariat.

Poster Sessions:

All posters will be on display throughout the congress.

The programme contains 2 poster sessions. Even poster numbers are presented on Monday evening, April 18th and odd poster numbers on Tuesday evening, April 19th.

The numbers on the poster boards correspond with the abstract/poster numbers in the NTMM supplement you will receive upon registration. Please mount your poster on the corresponding poster board as of Monday April 18th, 9:00 hours but no later than 19:00 hours. The poster should be PORTRAIT style. Landscape poster can NOT be displayed.

The maximum poster size is: 90 x 120 cm (WIDTH x HEIGHT)

Directly after the poster session on Tuesday the poster prizes will be announced.

There are 3 poster prizes: the 1st prize is Euro 200 and the 2nd and 3rd prize Euro 100 each.

Posters may be removed on Wednesday 20 April as of 8:00 hours. Posters that haven't been removed at Wednesday April 20th, 17:00 hours will be removed by the organization.

Party Tuesday evening

The poster prize ceremony will be followed by a dance party open for all participants.

At 0:00 hours the Dutch Society of Microbiology celebrates her 100th anniversary.

Exhibition, lunch break, coffee/tea break

Coffee/tea will be available at the exhibition during the breaks. The lunch will be served at the exhibition during the lunch break. The exhibition is located in Room Sydney.

Hotel rooms

If you have reserved a hotel room in Papendal Hotel en Conference Centre you may collect the room key as of 13:00 hours at the front desk of the hotel. Please make sure to check out before 10:00 hours.

Papendal Hotel en Conference Centre


A route description can be found on www.congresscompany.com.

Papendal taxi

If you are travelling by train you may use a service of Papendal Hotel en Conference Centre called the "Papendal taxi". The Papendal taxi will bring you from Central Railway Station Arnhem to Papendal for Euro 11,00 per person one-way. If you would like to make use of this service, please call taxi company Linsen at 026 - 474 22 95 (mention the Papendal taxi). The taxi's can be found at the "Sonsbeek side" of the railway station. You have to pay at arrival at the hotel reception. The taxi driver will wait for a ticket you have to give him. At the end of congress you can order a Papendal taxi at the hotel reception to bring you to the railway station.

Bus

From Arnhem Central Station bus 105 (direction Harderwijk) will bring you directly to bus stop 'West End'. From that point, it is a 10 minute walk to Papendal Hotel and Conference Centre. From Monday to Friday, between 7 am and 6 pm, it is also possible to take bus 109 (direction Sportcentrum Papendal). This bus goes directly to Papendal. From the bus stop it is a 3 minute walk to the rear entrance of the hotel.



Scientific Programme

Monday 18 April 2011

- 09:00 - 10:00 Registration
- 10:00 - 10:25 Opening ceremony with his Royal Highness the Prince of Orange
- 10:20 - 10:25 Introduction to Joan W. Bennett
Jos van Strijp
- 10:25 - 10:45 History of Dutch Microbiology
Joan W. Bennett (USA)
- 10:45 - 11:15 Coffee/tea break**
- 11:15 - 11:25 Antonie van Leeuwenhoek (1632-1723): Discovery of microorganisms
Gijs Kuenen
- 11:25 - 12:15 The contemporary van Leeuwenhoek
J. Craig Venter (USA)
- 12:15 - 13:15 Lunch**
- 13:15 - 13:20 FEMS
Bernhard Schink, FEMS President
- 13:20 - 13:25 Martinus Beijerinck (1851-1931): Discovery of viruses
Lesley Robertson
- 13:25 - 14:15 The contemporary Beijerinck
Harald zur Hausen (Germany)
- 14:15 - 14:25 Johanna Westerdijk (1883-1961): Microbial Interactions
Francine Govers
- 14:25 - 15:15 Origin of the eukaryotic cells in the mid-Proterozoic Eon
Lynn Margulis (USA)
- 15:15 - 15:45 Coffee/tea break**
- 15:45 - 15:55 Christiaan Eijkman (1858-1930): Bacteriology
Jos van Strijp
- 15:55 - 16:55 The contemporary Eijkman
Barry Marshall (Australia)
- 16:55 - 17:05 Albert Kluyver (1888-1956) and Cornelis van Niel (1897-1985): Unity in Biochemistry
Jack Pronk
- 17:05 - 18:05 The contemporary Kluyver & van Niel
Paul Nurse (United Kingdom)
- 18:05 - 18:10 Closing ceremony
Jos van Strijp
- 18:10 - 18:25 Future of Dutch microbiology and the NVvM
Huub Schellekens
- 18:25 - 19:30 Reception**
- Restaurant**
- 19:30 - 21:30 Dinner**
- 21:30 - 23:00 Poster session - even poster numbers**

Tuesday 19 April 2011

08:30 - 09:00 Registration

09:00 - 11:00 Parallel sessions

Athene B/C Gut commensals - the good, the bad and the unknown

Chairs: W. van Schaik & R. Willems

09:00 - 09:30 Enterococcal Diversity: Understanding the emergence of multidrug resistant strains by knowing their roots

M.S. Gilmore (USA)

09:30 - 10:00 Our other genome - the MetaHIT catalog of intestinal bacterial genes

S.D. Ehrlich (France)

10:00 - 10:30 Lactobacilli in the small intestine, and how we respond to them

M. Kleerebezem

10:30 - 10:45 IS-pro: fully automated analysis of the human intestinal microbiota

A.E. Budding

10:45 - 11:00 Human in vivo responses to commensal and probiotic lactobacilli

P. van Baarlen

Athene A Antibiotics and the bacterial cell envelope, a mixed blessing

Chair: B.J. Appelmek

09:00 - 09:30 Molecular transport across porins: Rate limiting interactions

M. Winterhalter (Germany)

09:30 - 10:00 Intervention opportunities in the mycobacterial cell envelope

L. Kremer (France)

10:00 - 10:30 Lipid II as target for (l)antibiotics

E.J. Breukink

10:30 - 10:45 Expression of multidrug resistance ABC transporter genes in *Bacillus subtilis*

E. Reilman

10:45 - 11:00 Comprehensive identification of genes required for antibiotic resistance and bile tolerance in the nosocomial pathogen *Enterococcus faecium*

X. Zhang

Room 4/5 Molecular microbiology

Chair: H.A.B. Wösten

09:00 - 09:30 The membrane potential is important for bacterial cell division

L.W. Hamoen

09:30 - 09:45 Isolation of a prokaryotic cell organelle from the uniquely compartmentalized anammox bacteria

S. Neumann

09:45 - 10:00 Mapping the interactions of the Twin-arginine translocation system (Tat) in *Bacillus subtilis*

C.G. Monteferrante

10:00 - 10:15 A model to study drug-induced mitochondrial dysfunction

R. de Boer

10:15 - 10:30 Gel-free proteomic identification of the *Bacillus subtilis* insoluble spore coat protein fraction.

W. Abhyankar

10:30 - 10:45 Protein complexes involved in membrane-bound electron transport of anammox bacteria

N. de Almeida

10:45 - 11:00 Heterogeneity in micro-colonies of *Aspergillus niger* in liquid shaken cultures
G.J. Veluw

Room 6/7 **WOGIZ: Public health consequences of molecular diagnosis in gastroenteritis**
Chairs: S.B. Debast & M. Scholing

09:00 - 09:30 Consequences of implementation of molecular diagnostics of gastroenteritis outside and inside the laboratory

J.F.L. Weel

09:30 - 10:00 Improved detection of five major gastrointestinal pathogens by use of a molecular screening approach

R.F. de Boer

10:00 - 10:15 About STEC Working Group and Shigella outbreaks

J.H. van Zeijl

10:15 - 10:30 Case control study gastroenteritis

L.E.S. Bruijnesteijn van Coppenraet

10:30 - 10:45 Realtime PCR reveals the presence of three distinct *Brachyspira* species in human spirochaetosis

L.J. Westerman

10:45 - 11:00 Reduction of workload of microbial gastroenteritis diagnostics by molecular pre-screening

W.A. Reijnen

Room 8/9 **Polymicrobial interactions during human health and disease**
Chair: D.A. Diavatopoulos

09:00 - 09:30 Interactions between respiratory bacteria and pneumovirus infections: Consequences for the pathogenesis of RSV- and HMPV-mediated severe disease

R.L. de Swart

09:30 - 10:00 Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity

T.B. Clarke

10:00 - 10:30 The human GI tract microbiota in health and disease

E.G.Z. Zoetendal

10:30 - 11:00 Discussion

Room 3 **Antimicrobial resistance 1**

Chair: M.A. Leverstein - van Hall

09:30 - 09:45 Phosphatidylglycerol derived lipids are key to weak organic acid stress resistance in *Bacillus subtilis*

J.W.A. Beilen

09:45 - 10:00 Serotype related variation in *Streptococcus pneumoniae* susceptibility to human antimicrobial peptide LL-37 cathelicidin

P. Huizinga

10:00 - 10:15 Macrolide resistance determination and molecular typing of *Mycoplasma pneumoniae* by pyrosequencing

E.B.M. Spuesens

10:15 - 10:30 Retrospective analysis of candidemia in a tertiary medical center, 2004-2010 and its implications for empirical treatment.

P.R. Goswami

10:30 - 10:45 Functional metagenomic analysis of the reservoir of antibiotic resistance genes in intensive care unit patients

E.B. Buelow

- 10:45 - 11:00 Colistin resistance in gram-negative bacteria (GNB) during prophylactic colistin use in Intensive Care Units (ICU)
E.A.N. Oostdijk
- 11:00 - 11:15 High rates of intestinal colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in patients at a tertiary-care hospital in Israel
M. Gazin
- 11:15 - 11:30 **Discussion**
- 11:00 - 11:30 **Coffee/tea break**
- 11:30 - 13:30 **Parallel sessions**
- Athene B/C (R)evolution in vaccines**
Chairs: A.J.W. van Alphen & A.D.M.E. Osterhaus
- 11:30 - 12:00 Influenza vaccines
A.D.M.E. Osterhaus
- 12:00 - 12:30 Vaccines against vector-borne diseases
G. Sutter (Germany)
- 12:30 - 13:00 Polio eradication by vaccination
P.D. Minor (United Kingdom)
- 13:00 - 13:15 Possible important differences in cellular immune responses after the change in the vaccination programme from the whole cell pertussis vaccine to an acellular vaccine
A.M. Buisman
- 13:15 - 13:30 Long-lasting sterile protection and cellular immune responses against *P. falciparum* malaria in human volunteers
M.B.B. McCall
- Athene A Biofilms**
Chairs: T. Abee & O.P. Kuipers
- 11:30 - 12:00 Biofilms of Gram-negative pathogens
J.M. Ghigo (France)
- 12:00 - 12:30 Biofilm formation in *Salmonella enterica* serovar Typhimurium - more than a bacterial lifestyle
U. Römling (Sweden)
- 12:30 - 13:00 Architecturally complex colony development in *Bacillus subtilis*
A.T. Kovacs
- 13:00 - 13:15 Mechanisms in *Listeria monocytogenes* biofilm formation and disinfectant resistance
S. van der Veen
- 13:15 - 13:30 Biofilm development on new and cleaned membrane surfaces
L.A. Bereschenko
- Room 4/5 Fishing for parasites**
Chair: L.M. Kortbeek
- 11:30 - 12:00 Codfish cooked slowly
L.M. Kortbeek
- 12:00 - 12:30 Fever and eosinophilia after visiting Italy
A.M. Vondeling
- 12:30 - 13:00 Epidemiological and clinical aspects of opisthorchiasis in Italy
E. Pozio (Italy)

- 13:00 - 13:15 Salmon surprise
J.J. Verweij
- 13:15 - 13:30 Toxocara and Ascaris seropositivity among patients suspected of visceral and ocular larva migrans in the Netherlands: trends from 1998 to 2009
E. Pinelli

Room 6/7 **Eco-physiology**
Chair: M.S.M. Jetten

- 11:30 - 12:00 Ecophysiology and genomics of key nitrite-oxidizing bacteria
H. Daims (Austria)
- 12:00 - 12:15 Analysis of bacterial and archaeal diversity in coastal microbial mats by using massive parallel 16S rRNA gene tag-sequencing
H.B. Henk
- 12:15 - 12:30 Enrichment of nitrite-dependent methane oxidizers from an acidic peatland
B. Zhu
- 12:30 - 12:45 Symbiosis in marine sponges: intimacy or flirts?
D. Sipkema
- 12:45 - 13:00 Metabolic engineering of the cyanobacterium *Synechocystis* sp. PCC 6803: Modification of its carbon metabolism for the synthesis of fermentation products
S.A. Angermayr
- 13:00 - 13:15 Biopolymer utilization by planktonic and biofilm bacteria in oligotrophic freshwater environments
E.L.W. Sack
- 13:15 - 13:30 Methylacidiphilum fumariolicum SolV uses the Calvin cycle for carbon assimilation
A.F. Khadem

Room 8/9 **Microbiology in International Public Health: Dutch Input**
Chair: E.C. Bowles

- 11:30 - 12:00 International collaboration: a necessity in public health and especially in infectious diseases
R.A. Coutinho
- 12:00 - 12:30 Inappropriate antibiotic use and resistance in Asia and it's global impact; a delicate balance of antibiotic accessibility
H.F.L. Wertheim (Vietnam)
- 12:30 - 12:45 Goulash and Boerenkool, an evaluation of the Netherlands-Hungary microbiology exchange program
G.J.H.M. Ruijs
- 12:45 - 13:00 Clinical Microbiology from a Dutch and German perspective
W.E. Silvis
- 13:00 - 13:15 Human Enterovirus 71: Europe versus Asia
S.M.G. van der Sanden
- 13:15 - 13:30 Molecular surveillance of multidrug resistant tuberculosis in the European Union; identification of a major clone and quality of VNTR typing
J.L. de Beer

Room 3 **Clinical microbiology 1**
Chair: M.J.H.M. Wolfhagen

- 11:30 - 11:45 Discriminating Lyme neuroborreliosis from other neuro-inflammatory diseases using levels of CXCL13 in cerebrospinal fluid
N.D. van Burgel

- 11:45 - 12:00 Increased frequency of positive Lyme serology in patients with aspecific skin lesions
A.P. van Dam
- 12:00 - 12:15 Measuring T-cell Responses in Q fever using a newly developed ELISPOT assay
J.J.M. Bouwman
- 12:15 - 12:30 Potential value of an ELISPOT interferon gamma release assay as a diagnostic tool in Q fever infection
G.J.M. Limonard
- 12:30 - 12:45 Low prevalence of *Coxiella burnetii* endocarditis in patients with a history of valve surgery or cardiac valve prosthesis in a Q fever endemic area
L.M. Kampschreur
- 12:45 - 13:00 QSZB study: a cross-sectional study of Q fever in patients with an aneurysm, vascular and/or heart valve prostheses in an endemic region
M.C.A. Wegdam-Blans
- 13:00 - 13:30 Discussion

13:30 - 14:30 Lunch

Athene A

13:30 - 14:30 NVvM Business meeting

14:30 - 16:30 Parallel sessions

Athene B/C Antimicrobial resistance in the environment and humans: Food for thought

Chair: C.M.J.E. Vandenbroucke-Grauls

- 14:30 - 15:00 Resistance in Gram-negative bacteria: An inconvenient truth
J. Kluytmans
- 15:00 - 15:30 How little we know about gene dissemination!
A. Andremont (France)
- 15:30 - 16:00 How little we know about epidemiology of *E. coli*!
N. Frimodt-Møller (Denmark)
- 16:00 - 16:15 Prevalence of ESBL-producing Enterobacteriaceae (ESBL-E) in Raw Vegetables
E.A. Reuland
- 16:15 - 16:30 Prevalence of extended-spectrum Beta-lactamase producing Enterobacteriaceae in faecal samples of patients in the community
I. Overdevest

Athene A Viral zoonoses

Chair: M.P.G. Koopmans

- 14:30 - 15:00 New zoonoses from a birds- eye perspective
A.D.M.E. Osterhaus
- 15:00 - 15:30 Of mice and mast: Epidemiology of hantaviruses in North-West Europe
C.B.E.M. Reusken
- 15:30 - 15:45 Only two residues are responsible for the dramatic difference in receptor binding between swine and new pandemic H1 hemagglutinin
R.P. de Vries
- 15:45 - 16:00 Immature Dengue virus: A veiled pathogen
I.A. Rodenhuis
- 16:00 - 16:15 Emergence and spread of human adaptation markers in avian influenza viruses during an HPAI A(H7N7) virus outbreak
M. Jonges
- 16:15 - 16:30 Discussion

Room 4/5 Under your skin: Parasites and skin problems

Chair: *L.M. Kortbeek*

- 14:30 - 15:00 Skin manifestations of parasitic diseases: What you should know, how to diagnose
P.J. de Vries
- 15:00 - 15:30 Photodynamic therapy in cutaneous leishmaniasis
E.M. van der Snoek
- 15:30 - 16:00 How do maggots operate?
G. Cazander
- 16:00 - 16:15 Presence of *Pneumocystis jiroveci* colonization in patients with chronic obstructive pulmonary disease
M.J. Vanspauwen
- 16:15 - 16:30 A real-time PCR on the SSU rRNA (18S) gene for cestode detection
J.H. Roelfsema

Room 6/7 Morphogenesis of bacteria

Chair: *D. Claessen*

- 14:30 - 15:00 Transport of peptidoglycan units across the bacterial membrane
E.J. Breukink
- 15:00 - 15:30 Regulation of peptidoglycan synthesis by outer membrane proteins
T. den Blaauwen
- 15:30 - 16:00 Positive control of cell division: FtsZ is recruited by SsgB during sporulation of *Streptomyces*
G.P. van Wezel
- 16:00 - 16:15 Regulation of FtsZ ring formation
D.-J. Scheffers
- 16:15 - 16:30 Activity and localization of the pneumococcal Ser/Thr protein kinase StkP is controlled by its PASTA domains
J.W. Veening

Room 8/9 @evolution in microbial education (www.nvvmonderwijs.nl)

Chair: *A.J.W. van Alphen*

- 14:30 - 15:00 Is microbiology gendered?
J.W. Bennett (USA)
- 15:00 - 15:30 Tele-microbiology for developing countries
M.D. de Jong
- 15:30 - 16:00 How to build a bacterium
O.P. Kuipers
- 16:00 - 16:30 Microbiology outreach - how the mushroom got its spots and other stories
S. Assinder (United Kingdom)

Room 3 Microbial pathogenesis 1

Chair: *P.W.M. Hermans*

- 14:30 - 14:45 The hypothetical proteases PA0572 of *Pseudomonas aeruginosa* cleaves P-selectin glycoprotein ligand-1
B.W. Bardoel
- 14:45 - 15:00 Epstein-Barr virus protein BNLF2a exploits host tail-anchored protein integration machinery for T cell evasion
D. Horst

- 15:00 - 15:15 Nuclease expression by *Staphylococcus aureus* promotes escape from neutrophil extracellular traps
E.T.M. Berends
- 15:15 - 15:30 Pneumococcal meningitis: interactions between *Streptococcus pneumoniae* and the blood-brain barrier
G. Molema
- 15:30 - 15:45 TroA of *Streptococcus suis* is required for efficient manganese acquisition and for full virulence
P.J. Wichgers Schreur
- 15:45 - 16:00 Host - pathogen interactions with *Streptococcus pneumoniae* during colonization and infection in an elderly mouse model
C.L. Krone
- 16:00 - 16:16 Structural insights on the *Mycobacterium tuberculosis*: the EspB substrate component
M. Sani
- 16:15 - 16:30 Metabolites of commensal bacteria modulate the TLR response in epithelial cells
M.Y. Lin
- 16:30 - 17:00 Coffee/tea break**

Room 6/7

- 17:00 - 17:30 A Clubhouse for Microbiologists: Special lecture on the The Microzoo, a future initiative of Artis Zoo Amsterdam
H. Balian & K. Greven
- 17:30 - 18:00 Award ceremony: SKMM Kwaliteit Prijs Medische Microbiologie

Room Sydney

- 18:00 - 19:00 Drinks**

Athene B/C

- 19:00 - 21:00 Dinner**

Foyer

- 21:00 - 22:30 Poster session odd posternumbers & poster award**

Athene C

- 22:30 - 01:30 Party**
00:00 100th Anniversary NVvM

Wednesday 20 April 2011

08:30 - 09:00 Registration

09:00 - 11:00 Parallel sessions

Athene B/C Livestock associated MRSA: A sheep in wolveskin?

Chair: J. Kluytmans

09:00 - 09:30 Livestock-associated MRSA: The European situation

R. Skov (Denmark)

09:30 - 10:00 Pig MRSA (ST398) - a sheep in wolf skin and the human MSSA (ST398) - a wolf in sheepskin?

F. Lowy (USA)

10:00 - 10:30 MRSA carriage and occurrence of disease in swine veterinarians

E.J.M. Verkade

10:30 - 10:45 Methicillin-resistant coagulase-negative Staphylococci isolated from pig farms in the Netherlands are a potential reservoir of *mecA* for *Staphylococcus aureus*

P. Tulinski

10:45 - 11:00 Typing of methicillin-resistant *Staphylococcus aureus* sequence type 398 isolates with a new optical mapping technique

T. Bosch

Athene A New human retroviruses

Chair: C.A.B. Boucher & J.M.D. Galama

09:00 - 09:30 Human tumor viruses and rumor viruses

R.A. Weiss (United Kingdom)

09:30 - 10:00 Beneficial and detrimental effects of human endogenous retroviruses

R. Kurth (Germany)

10:00 - 10:15 No XMRV in a well established cohort of CFS patients in the Netherlands

J.M.D. Galama

10:15 - 10:30 RNAi gene therapy for HIV-1: escape and countermeasures

B. Berkhout

10:30 - 10:45 HIV-1: old foe repackaged?

H. Schuitemaker

10:45 - 11:00 Discussion

Room 4/5 The granuloma in infectious diseases

Chair: A.M. van der Sar

09:00 - 09:30 The role of macrophages in granuloma formation

S. Gordon (United Kingdom)

09:30 - 10:00 The granuloma in tuberculosis: a host-pathogen collusion

S. Ehlers (Germany)

10:00 - 10:30 *Schistosoma mansoni* egg glycoproteins induce type-2 granulomas *in vivo* by a glycan-dependent mechanism

C.H. Hokke

10:30 - 10:45 Zebrafish embryo screen to identify mycobacterial genes involved in granuloma formation

E.J.M. Stoop

10:45 - 11:00 Disruption of *M. marinum* ESX-5 leads to increased granuloma formation and bacterial growth in adult zebrafish

E.M. Weerdenburg

Room 6/7 **Stressing microbes**

Chair: *S. Brul*

- 09:00 - 09:30 Lipid signaling regulated by pH: Phosphatidic acid as a pH biosensor
C.J.R. Loewen (Canada)
- 09:30 - 10:00 Regulation of cellular signaling and cell growth through cytosolic pH
R. Dechant (Switzerland)
- 10:00 - 10:15 Intracellular pH controls yeast growth
G.J. Smits
- 10:15 - 10:30 Weak acid stress in Bacilli
A.S. ter Beek
- 10:30 - 10:45 Prediction of stress induced robustness using molecular biomarkers
H.M.W. Besten
- 10:45 - 11:00 How dead is dead? A multiparameter viability toolbox applied to *Listeria monocytogenes*
R. Kort

Room 8/9 **Fungal biodiversity and genomics**

Chair: *R.P. de Vries*

- 09:00 - 09:30 Genomic approaches for the characterization of classical genetic mutants and metabolic pathways in filamentous fungi
S.E. Baker (USA)
- 09:30 - 10:00 Comparative transcriptome analysis between the opportunistic pathogen *Aspergillus fumigatus* and the rarely pathogenic *Aspergillus nidulans*
G.D. Robson (United Kingdom)
- 10:00 - 10:15 Meiotic recombination in sexual progeny of *Aspergillus fumigatus*
S.M.T. Camps
- 10:15 - 10:30 Azole-resistance in *Aspergillus fumigatus*: collateral damage of fungicide use?
E. Snelders
- 10:30 - 10:45 A cosmopolitan *Burkholderia terrae* equipped as universal migrator along different fungal hyphae
R. Nazir
- 10:45 - 11:00 Daqu - a fermentation starter for Chinese liquor fermentation
M.J.R. Nout

11:00 - 11:30 **Coffee/tea break**

11:30 - 13:30 **Parallel sessions**

Athene B/C Microbial pathogenesis 2

Chair: *J.A.G. van Strijp*

- 11:30 - 11:45 Profiling of global interactions between human serum proteins and the *Staphylococcus aureus* cell surface
G. Buist
- 11:45 - 12:00 Identification of genes essential for *Moraxella catarrhalis* survival under iron-limiting conditions
S.P.W. Vries
- 12:00 - 12:15 Secretion of virulence factors in pathogenic mycobacteria: Type VII substrates are recognized by multiple secretion signals
H. Daleke

- 12:15 - 12:30 Staphylococcal secreted protease aureolysin mediates immune evasion by cleaving complement C3
A.J. Laarman
- 12:30 - 12:45 Comparison of effectiveness of oral, nasal and subcutaneous infection routes of *Coxiella burnetii* in goats
H.I.J. Roest
- 12:45 - 13:00 Serum lipoproteins neutralize the virulence of Staphylococcal Phenol-Soluble-Modulins
B.G.J. Surewaard
- 13:00 - 13:15 Exploring the transcriptome and proteome of *Bordetella pertussis*, the causative agent of whooping cough
D. de Gouw
- 13:15 - 13:30 The DNA-binding and -cleavage activities of the *Mycoplasma genitalium* Holliday junction resolvase (RecU) are biochemically uncoupled
C. Vink

Athene A Varicella Zoster virus: Known and unknown aspects

Chair: Ph.H. Rothbarth

- 11:30 - 12:00 Varicella Zoster Virus and the Central Nervous System
M.A. Nagel (USA)
- 12:00 - 12:30 Vaccination against herpes zoster, pros and cons.
W. Opstelten
- 12:30 - 12:45 Guideline varicella 2010 - what's new?
Ph.H. Rothbarth
- 12:45 - 13:00 Diagnosis of Neurological VZV Disease
M.A. Nagel (USA)
- 13:00 - 13:15 Compartmentalization of aciclovir-resistant Varicella Zoster Virus: implications for sampling in molecular diagnostics
A.A.T.P. Brink
- 13:15 - 13:30 How to keep Varicella out of the hospital
N. Hartwig

Room 4/5 Hand hygiene: Why, when and how!

Chairs: R.R. Beumer & W.C. Hazeleger

- 11:30 - 12:00 Improvement of hand hygiene in hospital and health care settings
D. Pittet (Switzerland)
- 12:00 - 12:30 Hand hygiene: when, why, how
E. Todd (USA)
- 12:30 - 13:00 The virucidal efficacy of hand disinfectants
E. Tuladhar
- 13:00 - 13:30 Discussion

Room 6/7 System biology

Chair: B. Teustink

- 11:30 - 12:00 Microbial systems biology
B.O. Palsson (USA)
- 12:00 - 12:30 Flexibility of metabolic networks: genome-scale stoichiometric analysis of single species and a yoghurt consortium
F. Bruggeman

- 12:30 - 12:45 Multivariate approach for detecting interactions between of environmental parameters and composition of microbial communities
X. Wang
- 12:45 - 13:00 Curli fimbriae and cellulose production are influenced by environmental conditions and affect biofilm formation of *Salmonella enterica* subsp. *enterica* serovar Typhimurium
G.A.A. Castelijns
- 13:00 - 13:15 Interactions amongst marine archaeal and bacterial nitrifiers and anammox bacteria under oxygen limitation in a lab-scaled model system
J. Yan
- 13:15 - 13:30 How models can help to understand and improve the production of protein based bio-ingredients by the lactic acid bacterium *Lactococcus lactis*
L. Sijtsma

Room 8/9 **Clinical microbiology 2**

Chair: *B.J.M. Vlamincx*

- 11:30 - 11:45 Identification of biochemically inert non-fermentative bacteria derived from cystic fibrosis patients by matrix-assisted laser ionization/desorption time-of-flight mass spectrometry (MALDI-TOF MS)
S.Q. van Veen
- 11:45 - 12:00 Quantitative Mass Spectrometry reveals new therapeutic targets against the human fungal pathogen *Candida albicans*
C.J. Heilmann
- 12:00 - 12:15 Correlation between bacterial DNA load and severity of disease in *S. aureus* bacteraemia
W. Rozemeijer
- 12:15 - 12:30 Period of increased risk for *Clostridium difficile* infection after exposure to antibiotics
M.P.M. Hensgens
- 12:30 - 12:45 Male urinary tract infections in Dutch general practices
C.D.J. den Heijer
- 12:45 - 13:00 Comparison of two matrix-assisted laser desorption ionisation-time of flight mass spectrometry methods for the identification of clinically relevant anaerobic bacteria
M. Knoester
- 13:00 - 13:30 Discussion

13:30 - 14:30 **Lunch**

Athene A

13:30 - 14:30 **BBC-MMO Business Meeting**

14:30 - 16:30 **Parallel sessions**

Athene B/C **Microbial pathogenesis 3**

Chair: *W. Bitter*

- 14:30 - 15:00 C-type lectins in infection and immunity
T.B. Geijtenbeek
- 15:00 - 15:15 Immune modulating properties of mycobacterial type VII secretion systems
J. Bestebroer
- 15:15 - 15:30 Regulation of the energy metabolism in *C. jejuni*
M.M.S.M. Wösten
- 15:30 - 15:45 The pervasive effects of a *Citrobacter rodentium* infection on mouse gut microbial diversity
C. Belzer

- 15:45 - 16:00 Identification of immune modulators using a phage display library displaying *S. aureus* secreted proteins
C. Fevre
- 16:00 - 16:15 Bacterial evasion of Neutrophil Extracellular Traps: *Staphylococcus aureus* inhibits neutrophil elastase and myeloperoxidase
D.A.C. Stapels
- 16:15 - 16:30 Translocation into the cytosol novel pathogenicity factor mycobacteria
N.N. van der Wel

Athene A Polyomaviruses, known and new causes of infection in immunocompromized hosts
Chair: M.C.W. Feltkamp

- 14:30 - 15:00 Pathogenesis of JC-virus reactivation leading to PML
E.O. Major (USA)
- 15:00 - 15:30 Polyomavirus BK: Opportunity makes a Pathogen
H. Hirsch (Switzerland)
- 15:30 - 15:45 Identification and prevalence of a new human polyomavirus associated with trichodysplasia spinulosa
E. van der Meijden
- 15:45 - 16:00 The seroprevalence of seven high-risk HPV types in the Dutch population
M. Scherpenisse
- 16:00 - 16:15 Detection of Merkel cell polyomavirus in chronic lymphocytic leukemia cells by fluorescent in situ hybridization (FISH)
A. Haugg
- 16:15 - 16:30 Clinical features of wuv and kiv; pathogens or passengers?
A. Riezebos-Brilman

Room 4/5 Spatial spread of emerging clones and the consequences for typing
Chair: P.H.M. Savelkoul & B. Duim

- 14:30 - 15:00 Rapid pneumococcal evolution in response to clinical interventions
S. Bentley (United Kingdom)
- 15:00 - 15:30 Clonal expansions of MRSA
U. Nübel (Germany)
- 15:30 - 16:00 Continental scale dynamics
H. Grundmann
- 16:00 - 16:15 A quantitative account of genomic island acquisitions in prokaryotes
M.W.J. van Passel
- 16:15 - 16:30 Characterization of the penA mosaic gene in *Neisseria gonorrhoeae* strains with decreased susceptibility to cephalosporins in Amsterdam, the Netherlands
A.P. van Dam

Room 6/7 Antimicrobial resistance 2
Chair: M.A. Leverstein - van Hall

- 14:30 - 14:45 Evaluation of the Dutch surveillance on carbapenemase producing Enterobacteriaceae
M.A. Leverstein - van Hall
- 14:45 - 15:00 First detection of an Ambler class D OXA-48-type β -lactamase in a *Klebsiella pneumoniae* strain in The Netherlands
M. van Apeldoorn

- 15:00 - 15:15 Prevalence of tobramycin-resistant Enterobacteriaceae in a Dutch hospital: implications of the harmonised clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing
E.M.L. Verhaegh
- 15:15 - 15:30 Eradication of Extended-Spectrum Beta-Lactamases (ESBLs) during Selective Digestive tract Decontamination (SDD)
E.A.N. Oostdijk
- 15:30 - 15:45 Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains
M.A. Leverstein - van Hall
- 15:45 - 16:00 Comparison of ESBL contamination in organic and conventional retail chicken meat
J.W.T. Cohen Stuart
- 16:00 - 16:15 Characteristics of extended-spectrum cephalosporin-resistant clinical isolates from companion animals and horses
E. van Duijkeren
- 16:15 - 16:30 Discussion

Room 8/9 Interactive session on the field of medical microbiology & infectious diseases

Chairs: M.J.M. Bonten & B. Mulder

- 14:30 - 16:00 Interactive session
- 16:00 - 16:30 Interactive presentations of cases in infectious diseases by residents in training

16:30 - 17:00 Coffee/tea break

Athene B/C

17:00 - 18:00 NVMM Business meeting

Major Partners



Sponsors and exhibitors

Alere Health
Applied Maths
Astellas Pharma
BaseClear
BD
Beckman Coulter
Beldico
Bio Rad Laboratories
Bio Trading Benelux
Biologio
BioMérieux
Bodégro
Bruker Daltonics
Carl Zeiss
Cellestis
Cepheid Benelux
Check-Points
Clindia Benelux
CNC Grondstoffen
DiaSorin
DSM
Gen-Probe
Gilead Sciences
GlaxoSmithKline
I2a Benelux
Kiestra Lab Automation
Labolutions

Lucron Bioproducts
Luminex
Mediaproducts
Mediphos Medical Supplies
Menarini Diagnostics
Merck Sharp & Dohme
Meridian Bioscience
Minigrip Nederland
MIPS
MLS
New Brunswick Scientific Benelux
Oxoid
Pathofinder
Philips Healthcare
PIEXT
Qiagen Benelux
R-Biopharm
Roche Diagnostics
Salm en Kipp
Sarstedt
Siemens Healthcare Diagnostics
Snijders Scientific
Technidata Benelux
Tritium Microbiologie
Unilever
Westburg

Antonie van Leeuwenhoek Stichting



Medische vragen over een Pfizer geneesmiddel? Bel gratis Pfizer bv 0800-medinfo (633 46 36).


Referenties: 1. Herbrecht R et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med.* 2002;347:408-415.

Verkorte productinformatie VFEND (januari 2011). **Samenstelling:** VFEND 50 mg en 200 mg filmomhulde tabletten bevatten respectievelijk 50 mg en 200 mg voriconazol. VFEND i.v., poeder voor oplossing voor infusie, bevat 200 mg voriconazol per flacon, overeenkomend met een 10 mg/ml oplossing na reconstitutie. VFEND 40mg/ml poeder voor orale suspensie bevat per ml 40 mg voriconazol. **Indicaties:** Behandeling van invasieve aspergillose, candidemie bij niet-neutropenische patiënten, fluconazol-resistente ernstige invasieve *Candida*-infecties, ernstige schimmelinfecties, veroorzaakt door *Scedosporium* spp en *Fusarium* spp. VFEND dient in eerste instantie te worden toegediend aan patiënten met progressieve, mogelijk levensbedreigende infecties. **Farmacotherapeutische groep:** Antimycotica voor systemisch gebruik; triazolderivaten; ATC code: J02A C03. **Contra-indicaties:** Overgevoeligheid voor het werkzame bestanddeel of voor één van de hulpstoffen; gelijktijdige toediening van de CYP3A4-substraten terfenadine, astemizol, cisapride, pimozide, kinidine, en van rifampicine, carbamazepine, fenobarbital, ergotamine-alkaloiden (ergotamine, dihydro-ergotamine), ritonavir (in een dosering van tweemaal daags 400 mg en hoger) en sirolimus; gelijktijdig gebruik van voriconazol en sintjanskruid. Waarschuwingen en voorzorgen: Voorzichtigheid bij toediening aan patiënten met een overgevoeligheid voor andere azolen. Sommige azolen, met inbegrip van voriconazol, zijn geassocieerd met een verlenging van het QT-interval. Er deden zich zeldzame gevallen voor van torsade de pointes bij patiënten behandeld met voriconazol, die risicofactoren vertoonden en die gelijktijdig geneesmiddelen toegediend kregen die mogelijk aan deze voorvallen hadden bijgedragen. Voorzichtigheid is geboden bij de toediening van voriconazol aan patiënten met potentieel pro-arritmische factoren. Elektrolytstoornissen dienen voor aanvang van de behandeling met VFEND te worden gecontroleerd en gecorrigeerd. Ernstige hepatische reacties, die meestal reversibel zijn na staken van de VFEND toediening, kunnen optreden. Controle van de leverfunctie dient zowel bij kinderen als bij volwassenen en zowel bij aanvang van de behandeling als bij patiënten met abnormale leverfunctiewaarden routinematig tijdens de behandeling te worden uitgevoerd. Er zijn meldingen geweest van langdurige ongewenste voorvallen met betrekking tot het zicht, inclusief troebel zicht, optische neuritis en papilloedeem. Acut nierfalen kan voorkomen, daarom is een controle van de nierfunctie noodzakelijk. Patiënten, vooral kinderen, met risicofactoren voor acute pancreatitis dienen nauwkeurig gecontroleerd te worden tijdens behandeling met VFEND. Controle van serumamylase of -lipase kan worden overwogen. Patiënten ontwikkelden zelden exfoliatieve huidreacties tijdens VFEND behandeling. Bij uitbreiding van deze reacties dient VFEND toediening te worden gestopt. Daarnaast is VFEND geassocieerd met fototoxiciteit en pseudoporfyrie. Bij patiënten met fototoxiciteit en bijkomende risicofactoren werd plaveiselcarcinoom van de huid gemeld. Stopzetting van de behandeling met VFEND moet dan overwogen worden. Patiënten dienen tijdens de behandeling intense of langdurige blootstelling aan direct zonlicht te mijden en zo nodig maatregelen te nemen zoals beschermende kleding en zonnebrandcrème. Onder de leeftijd van twee jaar zijn de veiligheid en effectiviteit van VFEND niet aangetoond. Voriconazol is geïndiceerd voor pediatrische patiënten van twee jaar of ouder. De orale biologische beschikbaarheid kan beperkt zijn bij pediatrische patiënten van 2 tot <12 jaar met malabsorptie en een voor de leeftijd zeer laag lichaamsgewicht. In dat geval is de intraveneuze toediening van voriconazol aanbevolen. Bij gelijktijdig gebruik met fenytoïne of rifabutine wordt een zorgvuldige controle van de fenytoïnespiegels of volledige bloedceltelling (bij rifabutine) aanbevolen. Een frequente controle op methadongerelateerde ongewenste voorvallen en toxiciteit, waaronder QT-verlenging, wordt aanbevolen bij gelijktijdige toediening van voriconazol. Een dosisvermindering van methadon kan noodzakelijk zijn. Verlaging van de dosis alfentanil, fentanyl en andere kortwerkende opiaten die een op alfentanil gelijkende structuur hebben en door CYP3A4 gemetaboliseerd worden, dient te worden overwogen bij gelijktijdige toediening met voriconazol. Aangezien de halfwaardetijd van alfentanil viervoudig verlengd wordt wanneer alfentanil gelijktijdig met voriconazol wordt toegediend en aangezien het gelijktijdig gebruik van voriconazol met fentanyl resulteert in een verhoging van de gemiddelde AUC 0-∞ van fentanyl, kan het nodig zijn de opioïdgerelateerde bijwerkingen regelmatig te controleren (inclusief een langer toezicht op de ademhaling). Verlaging van de dosis oxycodon en andere langwerkende opiaten die door CYP3A4 gemetaboliseerd worden, dient te worden overwogen bij gelijktijdige toediening met voriconazol. Het kan nodig zijn de opioïdgerelateerde bijwerkingen regelmatig te controleren. De gelijktijdige toediening van oraal voriconazol en oraal fluconazol resulteert in een significante verhoging van de Cmax en AUC van voriconazol bij gezonde proefpersonen. Controle van de met voriconazol geassocieerde bijwerkingen is aanbevolen als voriconazol opeenvolgend na fluconazol wordt gebruikt. Gelijktijdige toediening van voriconazol en lage dosis ritonavir (tweemaal daags 100 mg) dient vermeden te worden, tenzij de risico/baatanalyse het rechtvaardigt. Wanneer voriconazol gelijktijdig met efavirenz wordt toegediend, dient de dosis voriconazol te worden verhoogd tot 400 mg om de 12 uur en dient de dosis van efavirenz te worden verlaagd tot 300 mg om de 24 uur. De tabletten bevatten lactose en mogen niet gebruikt worden bij Lapp-lactase deficiënte of glucose-galactose-malabsorptie patiënten. De orale suspensie bevat saccharose en mag niet gebruikt worden bij patiënten met zeldzame, erfelijke problemen van fructose-intolerantie, sucrose-isomaltase-deficiëntie of glucose-galactose-malabsorptie. **Bijwerkingen:** De meest gerapporteerde, zeer vaak voorkomende bijwerkingen (≥1/10) zijn: perifere oedeem, hoofdpijn, visusstoornis (inclusief troebel zicht, chromatopsie en fotofobie), buikpijn, misselijkheid, braken, diarree, huiduitslag en pyrexie. Verder zijn vaak (≥1/100, <1/10) waargenomen: verhoogde leverfunctiewaarden (met inbegrip van ASAT, ALAT, alkalische fosfatase, gammaGT, LDH, bilirubine), verhoogde bloedretininespiegel, pancytopenie, trombocytopenie, purpura, anemie, duizeligheid, verwardheid, tremor, agitatie, paresthesie, Acute respiratory distress'-syndroom, longoedeem, ademnoed, thoraxpijn, acut nierfalen, hematurie, exfoliatieve dermatitis, angioedem, lichtovergevoeligheidsreactie, maculo-papulaire huiduitslag, maculaire huiduitslag, papulaire huiduitslag, cheilitis, pruritus, alopecia, erythema multiforme, hypoglykemie, hypokaliëmie, gastro-enteritis, griepachtige symptomen, hypotensie, tromboflebitis, flebitis, reactie/ontsteking op de injectieplaats, rillingen, asthenie, sinusitis, glossitis, gezwollen tong, dyspepsie, constipatie, nefritis, proteinurie, syndroom van Stevens-Johnson, angioneurotisch oedeem, allergische dermatitis, urticaria, geneesmiddelovergevoeligheid, psoriasis, artritis, bijrijtorschorsinsufficiëntie, anafylactoïde reactie, overgevoeligheid, leverfalen, hepatitis, hepatomegalie, cholecystitis, cholelithiasis. Zelden (≥1/10.000, <1/1.000) komen voor: torsade de pointes, ventriculaire tachycardie, volledig atrioventriculaire blok, bundeltakblok, nodaal ritme, convulsie, encefalopathie, syndroom van Guillain-Barré, extrapyramidale symptomen, perifere neuropathie, slaperigheid tijdens infusie, retinaal bloeding, optische atrofie, oogdraaien, corneaotroebeling, hypoaacusis, tinnitus, dysgeusie, tubulaire necrose van de nier, toxische epidermale necrolyse, erythema multiforme, discoidale lupus erythematoses, pseudoporfyrie, hypertromie, hyperthyroïdie, hypothyroïdie, pseudomembraneuze colitis, lymfangitis, hepatisch coma, insomnie. **Afleveringsstatus:** U.R. **Verpakking en Registratienummer:** VFEND, filmomhulde tabletten 50 mg: EU/1/02/212/006 (30 stuks), filmomhulde tabletten 200 mg: EU/1/02/212/018 (30 stuks) VFEND, poeder voor oplossing voor infusie 200 mg: EU/1/02/212/025 (1 injectieflacon) VFEND, poeder voor orale suspensie: EU/1/02/212/026 (1 flacon). **Vergoeding en prijzen:** VFEND, filmomhulde tabletten en poeder voor orale suspensie worden volledig vergoed binnen het GVS, VFEND i.v. wordt vergoed volgens de 'Beleidsregel dure geneesmiddelen in ziekenhuizen'. Voor prijzen wordt verwezen naar de Z Index tax. **Voor medische informatie over dit product belt u met 0800-MEDINFO (6334636).** De volledige productinformatie (SPC van 20 december 2010) is op aanvraag verkrijgbaar. **Registratiehouder:** Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, Verenigd Koninkrijk. **N neem voor correspondentie en inlichtingen contact op met de lokale vertegenwoordiger: Pfizer bv, Postbus 37, 2900 AA Capelle a/d IJssel.**



Postbus 37
2900 AA Capelle aan den IJssel
www.pfizer.nl

Floorplan exhibition – Room Sydney




Booth number Company

1	Mediaproducts
2	Meridian Bioscience
3	Bruker Daltonics
4	I2a Benelux
5	Abbott Molecular
6	Bio Rad Laboratories
7	Biolegio
8	Snijders Scientific
9	Carl Zeiss
10	New Brunswick Scientific Benelux
11	Astellas Pharma
12	MLS
13	Labolutions
14	Cepheid Benelux
15	Siemens Healthcare Diagnostics
16	Beldico
17 + 18	DiaSorin
19	Tritium Microbiologie
20	Menarini Diagnostics
21	MIPS

Booth number Company

22	Alere Health
23	Technidata Benelux
24	Pfizer
25	Roche Diagnostics
26	Beckman Coulter
27	Lucron Bioproducts
28	R-Biopharm
29	Luminex
30	Qiagen Benelux
32	BD
33	Kiestra Lab Automation
34	Minigrip Nederland
35	Bodégro
36	Check-Points
37	Pathofinder
38	Applied Maths
39 + 40	Clindia Benelux
41	Sarstedt
42	Bio Trading Benelux
43	Oxoid


Floorplan exhibition – Foyer & 2



Booth number Company

- | | |
|----|---------------------------|
| 1 | Merck Sharp & Dohme |
| 2 | Gilead Sciences |
| 3 | Philips Heatcare |
| 4 | PiEXT |
| 5 | Salm en Kipp |
| 6 | Cellestis |
| 7 | Westburg |
| 10 | GlaxoSmithKline |
| 11 | Mediphos Medical Supplies |

Floorplan Papendal



Programme-at-a-glance

Monday April 18 2011		
		ROOM ATHENE A/B/C
09:00 - 10:00	Registration	
10:00 - 10:45		Plenary session
10:45 - 11:15	Coffee/tea	
11:15 - 12:15		Plenary session
12:15 - 13:15	Lunch	
13:15 - 15:15		Plenary session
15:15 - 15:45	Coffee/tea	
15:45 - 18:25		Plenary session
18:25 - 19:30	Reception	
19:30 - 21:30	Dinner	
21:30 - 23:00	Poster session	

Tuesday April 19 2011				
	EXHIBITION	ROOM ATHENE B/C	ROOM ATHENE A	ROOM 4
08:30 - 09:00	Registration			
09:00 - 11:00		Gut commensals – the good, the bad and the unknown	Antibiotics and the bacterial cell envelope, a mixed blessing	Molecular micro
11:00 - 11:30	Coffee/tea			
11:30 - 13:30		(R)evolution in vaccines	Biofilms	Fishing for pa
13:30 - 14:30	Lunch		NVvM Business Meeting	
14:30 - 16:30		Antimicrobial resistance in the environment and humans: Food for thought	Viral zoonoses	Under your Parasites and skin
16:30 - 17:00	Coffee/tea			
17:00 - 18:00				
18:00 - 19:00	Drinks			
19:00 - 21:00		Dinner		
21:00 - 22:30		Poster session		
22:30 - 01:30		Party		


Wednesday April 20 2011				
	EXHIBITION	ROOM ATHENE B/C	ROOM ATHENE A	ROOM 4
08:30 - 09:00	Registration			
09:00 - 11:00		Livestock associated MRSA: A sheep in wolveskin?	New human retroviruses	The granulo infectious dis
11:00 - 11:30	Coffee/tea			
11:30 - 13:30		Microbial pathogenesis 2	Varicella Zoster virus: Known and unknown aspects	Hand hygie Why, when an
13:30 - 14:30	Lunch		BBC-MMO Business Meeting	
14:30 - 16:30		Microbial pathogenesis 3	Polyomaviruses, known and new causes of infection in immunocompromized hosts	Spatial spread of em and the consequenc
16:30 - 17:00	Coffee/tea			
17:00 - 18:00		NVMM Business Meeting		

5	ROOM 6/7	ROOM 8/9	ROOM 3
Microbiology	WOGIZ: Public health consequences of molecular diagnosis in gastroenteritis	Polymicrobial interactions during human health and disease	Antimicrobial resistance 1
Parasites	Eco-physiology	Microbiology in International Public Health: Dutch Input	Clinical microbiology 1
Skin: problems	Morphogenesis of bacteria	*evolution in microbial education	Microbial pathogenesis 1
	Presentation about Microzoo & SKMM award ceremony		

5	ROOM 6/7	ROOM 8/9
Pha in diseases	Stressing microbes	Fungal biodiversity and genomics
Gene: and how!	System biology	Clinical microbiology 2
Emerging clones and typing	Antimicrobial resistance 2	Interactive session on the field of medical microbiology infectious diseases



VIROLOGY IS OUR WORLD



* in development

Put science on your side.

 **Abbott**
A Promise for Life



Creating a better future every day

Unilever's vision is to work to create a better future every day. We help people feel good, look good and get more out of life with brands and services that are good for them and good for others.

We will inspire people to take small everyday actions that can add up to a big difference for the world.

We will develop new ways of doing business that will allow us to double the size of our company while reducing our environmental impact.



Meet us at www.unilever.com/innovation